Loading...
Loading...
SERA| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.1M |
| Gross Profit | 0.0M |
| Operating Expense | 10.4M |
| Operating I/L | -10.4M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.2M |
| Pretax | -9.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -9.8M |
Sera Prognostics, Inc. is a women's health diagnostic company specializing in developing and commercializing biomarker tests to improve pregnancy outcomes. The company's flagship product, the PreTRM test, is a blood-based biomarker test designed to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. Additionally, Sera Prognostics is working on a range of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
